Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the company.
Several brokerages have issued reports on RBGLY. Sanford C. Bernstein lowered shares of Reckitt Benckiser Group from a "strong-buy" rating to a "hold" rating in a report on Monday, November 4th. Hsbc Global Res raised shares of Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a report on Wednesday, December 11th. HSBC raised shares of Reckitt Benckiser Group from a "hold" rating to a "buy" rating in a report on Wednesday, December 11th. Citigroup upgraded shares of Reckitt Benckiser Group to a "strong-buy" rating in a research note on Tuesday, October 1st. Finally, Barclays upgraded shares of Reckitt Benckiser Group to a "strong-buy" rating in a research note on Friday, October 4th.
Read Our Latest Report on RBGLY
Reckitt Benckiser Group Price Performance
RBGLY stock traded up $0.13 on Friday, reaching $12.69. 228,620 shares of the company were exchanged, compared to its average volume of 329,540. Reckitt Benckiser Group has a 12 month low of $10.24 and a 12 month high of $15.03. The stock's fifty day moving average price is $12.18 and its 200 day moving average price is $11.93. The company has a current ratio of 0.69, a quick ratio of 0.47 and a debt-to-equity ratio of 0.97.
About Reckitt Benckiser Group
(
Get Free ReportReckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Featured Articles
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
